BR112014028787A2 - método para tratamento de câncer de pulmão de célula não pequena - Google Patents

método para tratamento de câncer de pulmão de célula não pequena

Info

Publication number
BR112014028787A2
BR112014028787A2 BR112014028787A BR112014028787A BR112014028787A2 BR 112014028787 A2 BR112014028787 A2 BR 112014028787A2 BR 112014028787 A BR112014028787 A BR 112014028787A BR 112014028787 A BR112014028787 A BR 112014028787A BR 112014028787 A2 BR112014028787 A2 BR 112014028787A2
Authority
BR
Brazil
Prior art keywords
small cell
cell lung
lung cancer
treating
human patient
Prior art date
Application number
BR112014028787A
Other languages
English (en)
Portuguese (pt)
Inventor
Duksin Chen
Tessler Shoshi
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of BR112014028787A2 publication Critical patent/BR112014028787A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112014028787A 2012-05-18 2013-05-17 método para tratamento de câncer de pulmão de célula não pequena BR112014028787A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261649092P 2012-05-18 2012-05-18
PCT/US2013/041652 WO2013173757A1 (en) 2012-05-18 2013-05-17 Method for treating non-small cell lung cancer

Publications (1)

Publication Number Publication Date
BR112014028787A2 true BR112014028787A2 (pt) 2017-06-27

Family

ID=49581824

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014028787A BR112014028787A2 (pt) 2012-05-18 2013-05-17 método para tratamento de câncer de pulmão de célula não pequena

Country Status (17)

Country Link
US (1) US20130310440A1 (enExample)
EP (1) EP2849761A1 (enExample)
JP (1) JP2015522542A (enExample)
KR (1) KR20150024843A (enExample)
CN (1) CN104684564A (enExample)
AR (1) AR091090A1 (enExample)
AU (1) AU2013262589A1 (enExample)
BR (1) BR112014028787A2 (enExample)
CA (1) CA2874092A1 (enExample)
EA (1) EA201492148A1 (enExample)
IL (1) IL235459A0 (enExample)
IN (1) IN2014DN10390A (enExample)
PH (1) PH12014502569A1 (enExample)
SG (1) SG11201407649RA (enExample)
TW (1) TW201402132A (enExample)
UY (1) UY34812A (enExample)
WO (1) WO2013173757A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2300257T3 (es) 1999-02-26 2008-06-16 The University Of British Columbia Terapia antisentido contra trpm-2.
US7569551B2 (en) 2000-02-25 2009-08-04 The University Of British Columbia Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
ES3041855T3 (en) 2010-05-08 2025-11-17 Univ California Radiofrequency sensing method and apparatus for early detection of pressure ulcers
WO2012123823A1 (en) 2011-03-15 2012-09-20 The University Of British Columbia Combination of anti-clusterin oligonucleotide with hsp90 inhibitor for the treatment of prostate cancer
CN104473973B (zh) * 2014-12-19 2015-08-05 山东创新药物研发有限公司 一株戈氏梭菌驯化株的应用
CA2982249C (en) 2015-04-24 2019-12-31 Bruin Biometrics, Llc Apparatus and methods for determining damaged tissue using sub-epidermal moisture measurements
SG11201810082VA (en) * 2016-05-13 2018-12-28 Golden Biotechnology Corp Methods and compositions for treating advanced stage non-small cell lung cancer
DK3515306T3 (da) 2017-02-03 2025-01-27 Bbi Medical Innovations Llc Måling af modtagelighed for diabetiske fodsår
PT3515296T (pt) 2017-02-03 2023-12-18 Bbi Medical Innovations Llc Medição da viabilidade do tecido
JP6900477B2 (ja) 2017-02-03 2021-07-07 ブルーイン、バイオメトリクス、リミテッド、ライアビリティー、カンパニーＢｒｕｉｎ Ｂｉｏｍｅｔｒｉｃｓ， Ｌｌｃ コンパートメント症候群を評価するための装置、およびコンパートメント症候群を検出するためのコンピュータ可読媒体
AU2018368709C1 (en) * 2017-11-16 2025-07-17 Bruin Biometrics, Llc Providing a continuity of care across multiple care settings
WO2019136287A1 (en) * 2018-01-05 2019-07-11 LifeUnit Inc. Adjuvant chemicals that prevent drug tolerance and persister formation by bacteria
SI3749181T1 (sl) 2018-02-09 2024-06-28 Bruin Biometrics, LLC, Odkrivanje poškodb na tkivu
CN117596814A (zh) 2018-10-11 2024-02-23 布鲁恩生物有限责任公司 具有一次性元件的装置
WO2022169850A1 (en) 2021-02-03 2022-08-11 Bruin Biometrics, Llc Methods of treating deep and early-stage pressure induced tissue damage

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6900187B2 (en) * 1999-02-26 2005-05-31 The University Of British Columbia TRPM-2 antisense therapy using an oligonucleotide having 2′-O-(2-methoxy)ethyl modifications
US20060024692A1 (en) * 2002-09-30 2006-02-02 Oncotherapy Science, Inc. Method for diagnosing non-small cell lung cancers
WO2005094899A1 (en) * 2004-04-02 2005-10-13 The University Of British Columbia Clusterin antisense therapy for treatment of cancer
MX2010014228A (es) * 2008-06-18 2011-03-29 Abbott Laboratories Star Metodos y productos de diagnostico del p/gf-1 acompañante.
EP2709673A4 (en) * 2011-05-19 2014-12-17 Teva Pharma METHOD FOR THE TREATMENT OF NON-SMALL CELLULAR CANCER

Also Published As

Publication number Publication date
CN104684564A (zh) 2015-06-03
EP2849761A1 (en) 2015-03-25
KR20150024843A (ko) 2015-03-09
AU2013262589A1 (en) 2015-01-22
WO2013173757A8 (en) 2015-04-30
CA2874092A1 (en) 2013-11-21
US20130310440A1 (en) 2013-11-21
UY34812A (es) 2013-12-31
EA201492148A1 (ru) 2015-04-30
JP2015522542A (ja) 2015-08-06
PH12014502569A1 (en) 2015-01-21
TW201402132A (zh) 2014-01-16
AR091090A1 (es) 2014-12-30
IN2014DN10390A (enExample) 2015-08-14
IL235459A0 (en) 2014-12-31
WO2013173757A1 (en) 2013-11-21
SG11201407649RA (en) 2014-12-30

Similar Documents

Publication Publication Date Title
BR112014028787A2 (pt) método para tratamento de câncer de pulmão de célula não pequena
WO2011038160A3 (en) Compositions and methods for silencing genes expressed in cancer
WO2010129746A3 (en) Treatment of tristetraproline (ttp) related diseases by inhibition of natural antisense transcript to ttp
MX359548B (es) Agentes de iarn modificados.
MX358603B (es) Tratamiento de enfermedades relacionadas con un gen supresor de tumor mediante inhibicion del transcrito antisentido natural para el gen.
WO2016106406A3 (en) Rna agents for gst-pi gene modulation
WO2011163499A3 (en) Treatment of sodium channel, voltage-gated, alpha subunit (scna) related diseases by inhibition of natural antisense transcript to scna
WO2010129861A3 (en) Treatment of dystrophin family related diseases by inhibition of natural antisense transcript to dmd family
EP3800255A3 (en) Rna-guided transcriptional regulation and methods of using the same for the treatment of back pain
WO2012024396A3 (en) Compositions and methods for delivering nucleic acid molecules and treating cancer
WO2009111643A3 (en) Microrna markers for recurrence of colorectal cancer
MX354940B (es) Oligonucleotidos funcionalmente modificados y subunidades de los mismos.
WO2011091390A3 (en) Treatment of rnase h1 related diseases by inhibition of natural antisense transcript to rnase h1
WO2011103528A3 (en) Treatment of pyrroline-5-carboxylate reductase 1 (pycr1) related diseases by inhibition of natural antisense transcript to pycr1
WO2012009402A3 (en) Treatment of discs large homolog (dlg) related diseases by inhibition of natural antisense transcript to dlg
MX2013013384A (es) Metodo para tratamiento de cancer de pulmon de celulas no pequeñas.
WO2011082409A3 (en) Treatment of interferon regulatory factor 8 (irf8) related diseases by inhibition of natural antisense transcript to irf8
WO2011079261A3 (en) Treatment of hepatocyte growth factor (hgf) related diseases by inhibition of natural antisense transcript to hgf
WO2012006181A3 (en) Compositions and methods for inhibiting oncogenic micrornas and treatment of cancer
WO2012047956A3 (en) Treatment of sialidase 4 (neu4) related diseases by inhibition of natural antisense transcript to neu4
WO2012009347A3 (en) Treatment of bcl2 binding component 3 (bbc3) related diseases by inhibition of natural antisense transcript to bbc3
MX2019005101A (es) Microarns modificados con 5-halouracilo y su uso en el tratamiento del cancer.
WO2011017516A3 (en) Treatment of insulin gene (ins) related diseases by inhibition of natural antisense transcript to an insulin gene (ins)
MX2013010524A (es) Combinacion de oligonucleotido anti-clusterina con inhibidor hsp90 para el tratamiento de cancer de prostata.
WO2015032800A3 (en) Compositions and methods for inducing senescence in cancer cells

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 3A E 4A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]